The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Abstract
BACKGROUND: Zidovudine has been shown to prolong survival in patients with the acquired immunodeficiency syndrome (AIDS) and, in persons with human immunodeficiency virus (HIV) infection but not AIDS, to delay the progression to AIDS. However, it is still uncertain whether treatment before the development of AIDS prolongs survival. METHODS: We analyzed data from a cohort of 2162 high-risk men who were already seropositive for HIV type 1 (HIV-1) and 406 men who seroconverted from October 1986 through April 1991. There were 306 deaths. The probabilities of death were compared among men at similar stages of disease who began zidovudine therapy before the diagnosis of AIDS and among those who did not. Relative risks of death were calculated for each of five initial disease states on the basis of CD4+ cell counts and clinical symptoms and signs appearing over follow-up periods of 6, 12, 18, and 24 months. Adjustments were also made for the use of prophylaxis against Pneumocystis carinii pneumonia (PCP). RESULTS: After we controlled for CD4+ cell count and symptoms, the use of zidovudine with or without PCP prophylaxis before the development of AIDS significantly reduced mortality in all follow-up periods. The relative risks of death were 0.43 (95 percent confidence interval, 0.23 to 0.78) at 6 months, 0.54 (95 percent confidence interval, 0.38 to 0.78) at 12 months, 0.59 (95 percent confidence interval, 0.44 to 0.79) at 18 months, and 0.67 (95 percent confidence interval, 0.52 to 0.86) at 24 months. After we adjusted for the effects of PCP prophylaxis, zidovudine alone significantly reduced mortality at 6, 12, and 18 months (relative risks, 0.45, 0.59, and 0.70, respectively), but not at 24 months (relative risk, 0.81). Among zidovudine users, those who also used PCP prophylaxis before the development of AIDS had significantly lower mortality at 18 and 24 months than those who did not (relative risks, 0.62 and 0.60, respectively). CONCLUSIONS: The results of this study support the hypothesis that in HIV-1 infection, early treatment with zidovudine and PCP prophylaxis improves survival in addition to slowing the progression to AIDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Cited by
Hernán, M. Á., Brumback, B., & Robins, J. M. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00012 · Cited by 1,782
Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg, R. S. (1998) · JAMA · doi:10.1001/jama.279.6.450 · Cited by 850
Pathogenesis of human immunodeficiency virus infection
Levy, J. A. (1993) · Microbiological Reviews · doi:10.1128/mr.57.1.183-289.1993 · Cited by 839
Gallant, J. E., Moore, R. D., Richman, D. D., Keruly, J., Chaisson, R. E., & Zidovudine Epidemiology Study Group (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/166.6.1223 · Cited by 529
Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments
Hernán, M. A., Brumback, B., & Robins, J. M. (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753168154 · Cited by 493
Metadata
- Authors
- Graham, N. M. H., Zeger, S. L., Park, L. P., Vermund, S. H., Detels, R., Rinaldo, C. R., & Phair, J. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-04-16
- Volume
- 326
- Issue
- 16
- Pages
- 1037-1042
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993382722
- Cited by
- 212
- References
- 1
- FWCI
- 39.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199204163261601
- The paper
- Graham, N. M. H., Zeger, S. L., Park, L. P., Vermund, S. H., Detels, R., Rinaldo, C. R., & Phair, J. P. (1992). The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199204163261601
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.